Loading provider…
Loading provider…
Dermatology Physician in Miami, FL
NPI: 1154347847Primary Practice Location
Integrated Dermatology of South Miami LLC
7800 SW 87th Ave, Miami, FL
Primary Employer
Integrated Dermatology of South Miami LLC
mydermgroup.com
HQ Phone
Get M.D. Jill's Phone NumberMobile
Get M.D. Jill's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
FL State Medical License
FL State Medical License
2007 - 2026
OH State Medical License
2001 - 2009

American Board of Dermatology
Dermatology
Wright State University
Residency • Dermatology
2002 - 2005
Kettering Health Network/Kettering Medical Center
Internship • Transitional Year
2001 - 2002
Boonshoft School of Medicine
medicine.wright.edu
Medical School
Until 2001
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 142 | 176 |
| 2 | 17000Destruction of skin growth | 102 | 121 |
| 3 | 17003Destruction of 2-14 skin growths | 72 | 277 |
| 4 | 11102Tangential biopsy of single skin lesion | 70 | 75 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 65 | 76 |
Authors: Michael Abrouk
Journal: Lasers Surg Med
Authors: David Ozog
Journal: Dermatol Surg
Fractional laser resurfacing for thermal burns.
Authors: Kenneth Beer
Journal: J Drugs Dermatol
Lead Sponsor: Avita Medical
Intervention / Treatment: DEVICE: Control Intervention (UVB), DEVICE: Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
Lead Sponsor: Olix Pharmaceuticals, Inc.
Collaborators: Alira Health
Intervention / Treatment: DRUG: OLX10010
Lead Sponsor: Eli Lilly and Company
Collaborators: Dermira, Inc.
Intervention / Treatment: BIOLOGICAL: Lebrikizumab